<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29211216</article-id><article-id pub-id-type="pmc">5701095</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Cardiac Surgery in Jehovah's Witness Patients: Experience of a
Brazilian Tertiary Hospital</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Valle</surname><given-names>Felipe Homem</given-names></name><degrees>MD, ScD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pivatto J&#x000fa;nior</surname><given-names>Fernando</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Gomes</surname><given-names>Bruna Sessim</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Freitas</surname><given-names>Tanara Martins</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giaretta</surname><given-names>Vanessa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gus</surname><given-names>Miguel</given-names></name><degrees>MD, MSc, ScD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Hospital de Cl&#x000ed;nicas de Porto Alegre (HCPA), Cardiology
Division, Porto Alegre, RS, Brazil.</aff><aff id="aff2">
<label>2</label> Hospital de Cl&#x000ed;nicas de Porto Alegre (HCPA), Internal
Medicine Division, Porto Alegre, RS, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: Fernando Pivatto J&#x000fa;nior, Hospital de
Cl&#x000ed;nicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2.350, sala 700 -
Porto Alegre, RS, Brazil, Zip code: 90.035-903. E-mail:
<email>fpivatto@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2017</year></pub-date><volume>32</volume><issue>5</issue><fpage>372</fpage><lpage>377</lpage><history><date date-type="received"><day>13</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>5</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The outcomes of Jehovah's Witness (JW) patients submitted to open heart
surgery may vary across countries and communities. The aim of this study was
to describe the morbidity and mortality of JW patients undergoing cardiac
surgery in a tertiary hospital center in Southern Brazil.</p></sec><sec><title>Methods</title><p>A case-control study was conducted including all JW patients submitted to
cardiac surgery from 2008 to 2016. Three consecutive surgical non-JW
controls were matched to each selected JW patient. The preoperative risk of
death was estimated through the mean EuroSCORE II.</p></sec><sec><title>Results</title><p>We studied 16 JW patients with a mean age of 60.6&#x000b1;12.1 years. The
non-JW group included 48 patients with a mean age of 63.3&#x000b1;11.1 years
(<italic>P</italic>=0.416). Isolated coronary artery bypass graft
surgery was the most frequent surgery performed in both groups. Median
EuroSCORE II was 1.29 (IQR: 0.66-3.08) and 1.43 (IQR: 0.72-2.63),
respectively (<italic>P</italic>=0.988). The mortality tended to be higher
in JW patients (18.8% <italic>vs.</italic> 4.2%, <italic>P</italic>=0.095),
and there was a higher difference between the predicted and observed
mortality in JW patients compared with controls (4.1 and 18.8%
<italic>vs.</italic> 2.1 and 4.2%). More JW patients needed hemodialysis
in the postoperative period (20.0 <italic>vs.</italic> 2.1%,
<italic>P</italic>=0.039).</p></sec><sec><title>Conclusion</title><p>We showed a high rate of in-hospital mortality in JW patients submitted to
cardiac surgery. The EuroSCORE II may underestimate the surgical risk in
these patients.</p></sec></abstract><kwd-group><kwd>Jehovah's Witnesses</kwd><kwd>Cardiac Surgical Procedures</kwd><kwd>Mortality</kwd></kwd-group></article-meta></front><body><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">JW</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Jehovah's Witness</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HCPA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;= Hospital de
Cl&#x000ed;nicas de Porto Alegre</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SPSS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Statistical Package for
Social Sciences</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VAP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ventilator-associated
pneumonia</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Based on religious beliefs, Jehovah's Witness (JW) refuse blood products
transfusions. In some clinical situations, it may be both, a healthcare and an
ethical challenge. Despite the development in surgical techniques, more than 50% of
patients receive perioperative transfusion in cardiac surgeries<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>More recently, the data of case series<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup> and some controlled
studies<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r10" ref-type="bibr">10</xref>]</sup> showed that the perioperative and postoperative
prognosis of JW is similar to those of patients who do not have restrictions to
blood products transfusions. However, the rates of mortality and postoperative
complications in patients that undergo cardiac surgery are variable. Although
clinical results are determined largely by sample characteristics and by the
preoperative and postoperative care, assistant teams cultural and religious factors
may play a specific role in the surgical success of these patients. Therefore, the
evaluation of the cardiac surgery results in JW patients should be evaluated in
different cultural scenarios.</p><p>In Brazil, there are no studies that address local results in cardiovascular
procedures in such context. The 2010 Brazilian census<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> showed that 1,393,208 persons (0.73% of whole
population) were identified as JW. The aim of this study was to describe the
morbidity and mortality of JW patients undergoing cardiac surgery in a tertiary
hospital center of Porto Alegre, Southern Brazil, considering only the more
contemporary cases. We also compare the predicted mortality estimated by the
EuroSCORE II<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> in JW patients
and controls.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The current case-control study was carried out at the Hospital de Cl&#x000ed;nicas de
Porto Alegre (HCPA), a tertiary hospital in Southern Brazil (state of Rio Grande do
Sul), during the period from 2008 to 2016. All JW patients submitted to cardiac
surgery were selected. The patients' identification as JW occurred through surgical
schedules, bioethics consultations and keyword search in the electronic medical
records system. Three consecutive surgical non-JW controls were matched to each
selected JW patient, including only surgeries with extracorporeal circulation.</p><p>Preoperative risk of death was estimated through the mean EuroSCORE II<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Death during hospitalization,
regardless of its length, was defined as hospital mortality. The registry of at
least one of the following complications was considered as hospital morbidity:
creatinine &#x0003e; 2 mg/dL, mechanical ventilation &#x0003e; 48 hours, myocardial
infarction, need for either hemodialysis or intra-aortic balloon pump,
reintervention due to bleeding, reintubation, stroke and use of antibiotics.
Definitions of active endocarditis, chronic pulmonary disease, critical preoperative
state, surgery urgency, extracardiac arteriopathy and recent myocardial infarction
(&#x0003c; 90 days) were the used in the EuroSCORE II study<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Creatinine clearance was estimated through
Cockroft-Gault formula.</p><p>Data were collected directly from the patients' electronic charts, and analyzed in
the software Statistical Package for Social Sciences (SPSS) 21.0. Qualitative data
were reported as absolute and relative frequency; mean (&#x000b1; standard deviation)
or median (interquartile range) were used for quantitative variables. The comparison
of the groups was performed by Student's t-test for quantitative variables with
normal distribution, by Mann-Whitney U test, for the quantitative without normal
distribution and chi-square test for categorical variables. In situations of low
frequency, Fisher exact test was used. Normality of the distribution of each
variable was evaluated using Shapiro-Wilk test. The significance level adopted in
all tests was 5%. The present study was submitted and approved by the local Research
Ethics Committee.</p></sec><sec sec-type="results"><title>RESULTS</title><p>During the period under study, 16 JW patients were submitted to cardiac surgery at
the institution. The demographic characteristics of the whole sample are described
in <xref ref-type="table" rid="t1">Table 1</xref>. Patients were neither receiving
iron supplementation therapy nor were in critical state in the preoperative
period.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic characteristics of the sample.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">JW (n=16)</th><th align="center" rowspan="1" colspan="1">Non-JW (n=48)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">60.6&#x000b1;12.1</td><td align="center" rowspan="1" colspan="1">63.3&#x000b1;11.1</td><td align="center" rowspan="1" colspan="1">0.416</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex</td><td align="center" rowspan="1" colspan="1">9 (56.3)</td><td align="center" rowspan="1" colspan="1">32 (66.7)</td><td align="center" rowspan="1" colspan="1">0.652</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic hypertension</td><td align="center" rowspan="1" colspan="1">14 (87.5)</td><td align="center" rowspan="1" colspan="1">41 (85.4)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous smoking</td><td align="center" rowspan="1" colspan="1">6 (37.5)</td><td align="center" rowspan="1" colspan="1">29 (60.4)</td><td align="center" rowspan="1" colspan="1">0.192</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking (&#x0003c; 30 days)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">5 (10.4)</td><td align="center" rowspan="1" colspan="1">0.319</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic pulmonary disease</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary hypertension (&#x02265; 31 mmHg)</td><td align="center" rowspan="1" colspan="1">5 (31.2)</td><td align="center" rowspan="1" colspan="1">13 (27.1)</td><td align="center" rowspan="1" colspan="1">0.756</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous MI</td><td align="center" rowspan="1" colspan="1">5 (31.3)</td><td align="center" rowspan="1" colspan="1">15 (31.3)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Recent MI</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">10 (20.8)</td><td align="center" rowspan="1" colspan="1">0.265</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">4 (25.0)</td><td align="center" rowspan="1" colspan="1">17 (35.4)</td><td align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes on insulin</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">4 (8.3)</td><td align="center" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class III/IV heart failure</td><td align="center" rowspan="1" colspan="1">3 (18.7)</td><td align="center" rowspan="1" colspan="1">9 (18.8)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF</td><td align="center" rowspan="1" colspan="1">56.0 (37.5-67.0)</td><td align="center" rowspan="1" colspan="1">55.5 (42.2-68.7)</td><td align="center" rowspan="1" colspan="1">0.951</td></tr><tr><td align="left" rowspan="1" colspan="1">CCS class 4 angina</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">8 (16.7)</td><td align="center" rowspan="1" colspan="1">0.430</td></tr><tr><td align="left" rowspan="1" colspan="1">Unstable angina</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous heart surgery</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">2 (4.2)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">6 (12.5)</td><td align="center" rowspan="1" colspan="1">0.669</td></tr><tr><td align="left" rowspan="1" colspan="1">Extracardiac arteriopathy</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">6 (12.5)</td><td align="center" rowspan="1" colspan="1">0.669</td></tr><tr><td align="left" rowspan="1" colspan="1">Active endocarditis</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.250</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min)<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" rowspan="1" colspan="1">88.6 (50.4-102.3)</td><td align="center" rowspan="1" colspan="1">72.2 (55.1-98.9)</td><td align="center" rowspan="1" colspan="1">0.617</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative hemodialysis</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.250</td></tr><tr><td align="left" rowspan="1" colspan="1">Acetylsalicylic acid use</td><td align="center" rowspan="1" colspan="1">6 (37.5)</td><td align="center" rowspan="1" colspan="1">28 (58.3)</td><td align="center" rowspan="1" colspan="1">0.247</td></tr><tr><td align="left" rowspan="1" colspan="1">Erythropoietin use<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" rowspan="1" colspan="1">1 (6.7)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.238</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" rowspan="1" colspan="1">39.7 (35.2-42.6)</td><td align="center" rowspan="1" colspan="1">37.4 (33.1-41.7)</td><td align="center" rowspan="1" colspan="1">0.438</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" rowspan="1" colspan="1">13.6 (11.7-14.2)</td><td align="center" rowspan="1" colspan="1">12.7 (11.1-14.2)</td><td align="center" rowspan="1" colspan="1">0.571</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE II</td><td align="center" rowspan="1" colspan="1">1.29 (0.66-3.08)</td><td align="center" rowspan="1" colspan="1">1.43 (0.72-2.63)</td><td align="center" rowspan="1" colspan="1">0.988</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>CCS=Canadian Cardiovascular Society; JW=Jehovah's Witness; LVEF=left
ventricular ejection fraction; MI=myocardial infarction; NYHA=New York
Heart Association</p></fn><fn id="TFN2"><label>*</label><p>Excluding a chronic kidney disease on hemodialysis patient.</p></fn><fn id="TFN3"><p>Data presented as number (%), mean &#x000b1; standard deviation or median
(interquartile range).</p></fn></table-wrap-foot></table-wrap><p>Isolated coronary artery bypass graft surgery was the most frequent surgery performed
in both groups. Extracorporeal circulation and cross-clamp times were similar
between JW and non-JW groups. Surgical characteristics data are described in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Surgical data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">JW<break/>(n=16)</th><th align="center" rowspan="1" colspan="1">Non-JW<break/>(n=48)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Non-elective surgery</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">4 (8.3)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated CABG</td><td align="center" rowspan="1" colspan="1">7 (43.8)</td><td align="center" rowspan="1" colspan="1">28 (58.3)</td><td align="center" rowspan="1" colspan="1">0.469</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated biological AVR</td><td align="center" rowspan="1" colspan="1">3 (18.8)</td><td align="center" rowspan="1" colspan="1">6 (12.5)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated biological MVR</td><td align="center" rowspan="1" colspan="1">2 (12.5)</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CABG + biological AVR</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CABG + biological aortic valved graft</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated mechanical AVR</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">3 (6.3)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mechanical AVR + MVR</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated mechanical MVR</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">2 (4.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mechanical aortic valved graft +
aneurysmectomy</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CABG + aorta pseudoaneurysm correction</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mechanical aortic valved graft</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Biological aortic valved graft</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Heart tumor removal</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Interventricular communication correction</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Resection of subaortic membrane + septoplasty</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Extracorporeal circulation time (minutes)</td><td align="center" rowspan="1" colspan="1">58.5 (50.7-71.5)</td><td align="center" rowspan="1" colspan="1">67.5 (55.2-90.0)</td><td align="center" rowspan="1" colspan="1">0.139</td></tr><tr><td align="left" rowspan="1" colspan="1">Cross-clamp time (minutes)</td><td align="center" rowspan="1" colspan="1">38.5 (31.2-51.0)</td><td align="center" rowspan="1" colspan="1">48.0 (40.0-65.0)</td><td align="center" rowspan="1" colspan="1">0.054</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>AVR=aortic valve replacement; CABG=coronary artery bypass graft surgery;
JW=Jehovah's Witness; MVR=mitral valve replacement</p><p>Data presented as number (%) or median (interquartile range).</p></fn></table-wrap-foot></table-wrap><p>Hospital outcomes are presented in <xref ref-type="table" rid="t3">Table 3</xref>.
There was no statistically significant difference in the rate of mortality or
morbidity, with a trend to a higher mortality in the JW group. Causes of death were
septic (n=1), cardiogenic (n=1) and hypovolemic (n=1) shock in the JW group;
ischemic stroke (n=1) and right ventricle failure/shock (n=1) were responsible for
the deaths in the control group. The levels of both hematocrit and hemoglobin at
discharge were leveled between the two groups. Lengths of stay, considering both
intensive care unit and ward stay after surgery, were also similar between
groups.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Hospital outcomes.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">JW<break/>(n=16)</th><th align="center" rowspan="1" colspan="1">Non-JW<break/>(n=48)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mortality</td><td align="center" rowspan="1" colspan="1">3 (18.8)</td><td align="center" rowspan="1" colspan="1">2 (4.2)</td><td align="center" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" rowspan="1" colspan="1">Morbidity</td><td align="center" rowspan="1" colspan="1">4 (25.0)</td><td align="center" rowspan="1" colspan="1">14 (29.2)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Last hematocrit (%)</td><td align="center" rowspan="1" colspan="1">28.6 (23.6-33.6)</td><td align="center" rowspan="1" colspan="1">28.8 (26.5-32.9)</td><td align="center" rowspan="1" colspan="1">0.625</td></tr><tr><td align="left" rowspan="1" colspan="1">Last hemoglobin (g/dL)</td><td align="center" rowspan="1" colspan="1">9.2 (7.5-11.6)</td><td align="center" rowspan="1" colspan="1">9.4 (8.8-10.9)</td><td align="center" rowspan="1" colspan="1">0.593</td></tr><tr><td align="left" rowspan="1" colspan="1">Length of stay (days)</td><td align="center" rowspan="1" colspan="1">6.5 (6.0-9.5)</td><td align="center" rowspan="1" colspan="1">7.0 (7.0-9.7)</td><td align="center" rowspan="1" colspan="1">0.143</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>JW=Jehovah's Witness. Data presented as number (%) or median
(interquartile range).</p></fn></table-wrap-foot></table-wrap><p>The comparison of the predicted and observed mortality is shown in <xref ref-type="fig" rid="f1">Figure 1</xref>. As noted, unlike non-JW group, the
observed mortality was higher than the rate predicted by mean EuroSCORE II in the JW
group.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Comparison of the predicted and observed hospital mortality in JW and
non-JW patients accordingly EuroSCORE II.</p></caption><graphic xlink:href="rbccv-32-05-0372-g01"/></fig>
</p><p>The need for hemodialysis in the postoperative period was significantly higher in JW
patients, but the incidence of the other morbidities analyzed was similar between
the patients' groups. Detailed hospital morbidity per outcome is shown in <xref ref-type="table" rid="t4">Table 4</xref>. The reasons for antibiotic use were
septic shock due to central line infection (n=1) and ventilator-associated pneumonia
(VAP; n=1) in JW patients; respiratory tract infection (n=4), urinary tract
infection (n=2), surgical wound infection (n=2), VAP (n=1) and diverticulitis (n=1)
accounted for the use of antibiotics in the non-JW group.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Hospital morbidity.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Hospital morbidity</th><th align="center" rowspan="1" colspan="1">JW<break/>(n=16)</th><th align="center" rowspan="1" colspan="1">Non-JW<break/>(n=48)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mechanical ventilation &#x0003e; 48h</td><td align="center" rowspan="1" colspan="1">4 (25.0)</td><td align="center" rowspan="1" colspan="1">4 (8.3)</td><td align="center" rowspan="1" colspan="1">0.099</td></tr><tr><td align="left" rowspan="1" colspan="1">Need for hemodialysis<xref ref-type="table-fn" rid="TFN7">*</xref></td><td align="center" rowspan="1" colspan="1">3 (20.0)</td><td align="center" rowspan="1" colspan="1">1 (2.1)</td><td align="center" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" rowspan="1" colspan="1">Reintubation</td><td align="center" rowspan="1" colspan="1">3 (18.8)</td><td align="center" rowspan="1" colspan="1">3 (6.3)</td><td align="center" rowspan="1" colspan="1">0.159</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotic use<sup><xref ref-type="table-fn" rid="TFN8">&#x02020;</xref></sup></td><td align="center" rowspan="1" colspan="1">2 (13.3)</td><td align="center" rowspan="1" colspan="1">10 (20.8)</td><td align="center" rowspan="1" colspan="1">0.714</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine &#x0003e; 2 mg/dL<xref ref-type="table-fn" rid="TFN7">*</xref></td><td align="center" rowspan="1" colspan="1">1 (6.7)</td><td align="center" rowspan="1" colspan="1">4 (8.3)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Perioperative MI</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">2 (4.2)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Need for IABP</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.250</td></tr><tr><td align="left" rowspan="1" colspan="1">Reintervention for bleeding</td><td align="center" rowspan="1" colspan="1">1 (6.3)</td><td align="center" rowspan="1" colspan="1">3 (6.3)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">2 (4.2)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>JW=Jehovah's Witness; IABP=intra-aortic balloon pump; MI=myocardial
infarction</p></fn><fn id="TFN7"><label>*</label><p>Excluding a chronic kidney disease on hemodialysis patient.</p></fn><fn id="TFN8"><label>&#x02020;</label><p>Excluding an active endocarditis patient.</p></fn><fn id="TFN9"><p>Data presented as number (%).</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this case-control study, we reported the hospital outcomes of a non-selected group
of JW that were submitted to cardiac surgery in a Brazilian tertiary center between
2008 and 2016. Outcomes and demographic variables were compared with a matched
control group as described above. The rates of hospital mortality and morbidity were
leveled between JW and controls. However, there was a trend toward higher mortality
rate in JW than in controls (18.8 <italic>vs.</italic> 4.2%, respectively;
<italic>P</italic>=0.095). In addition, necessity of hemodialysis in the
postoperative period was greater in JW than in controls (20.0 <italic>vs.</italic>
2.1%, respectively; <italic>P</italic>=0.039). Moreover, it was observed that, in
JW, the mortality rates were higher than predicted by the EuroSCORE II. Hemoglobin
levels remained similar between groups, both preoperatively and at discharge.</p><p>Previous retrospective studies demonstrated that cardiac surgery might be performed
in JW with acceptable outcomes<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Furthermore, retrospective
studies that compared mortality and morbidity rates in JW and controls showed
leveled results between both groups<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Bhaskar et
al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> and Pattakos et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> compared outcomes
of JW with a control group of transfused patients. Marinakis et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> and Stamou et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> described outcomes of JW with a
matched group regardless of blood transfusion. <xref ref-type="table" rid="t5">Table
5</xref> shows a comparison of current study with previous retrospective
comparative studies. In agreement with previous comparative studies, we observed
similar levels of hemoglobin between groups, both preoperatively and at discharge.
Our results also showed similar rate of reoperation due to excessive bleeding in JW
and in controls. However, the in-hospital mortality rate in JW in our study was
higher than in previous studies. In addition, our report is the first to demonstrate
both higher necessity of hemodialysis in the postoperative period and a trend toward
higher mortality rate in JW than in controls. Notwithstanding, our cohort is the
first report that demonstrates higher mortality rates in JW than predicted by the
EuroSCORE II in all risk strata.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Comparison of current study with previous retrospective comparative
studies.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Valle et al. (current study)</th><th align="center" rowspan="1" colspan="1">Marinakis et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup></th><th align="center" rowspan="1" colspan="1">Stamou et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup></th><th align="center" rowspan="1" colspan="1">Bhaskar et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup></th><th align="center" rowspan="1" colspan="1">Pattakos et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">n</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">322</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">60.6&#x000b1;12.1</td><td align="center" rowspan="1" colspan="1">62&#x000b1;15</td><td align="center" rowspan="1" colspan="1">62.7&#x000b1;9.5</td><td align="center" rowspan="1" colspan="1">65.3&#x000b1;10.1</td><td align="center" rowspan="1" colspan="1">62&#x000b1;13</td></tr><tr><td align="left" rowspan="1" colspan="1">Isolated CABG</td><td align="center" rowspan="1" colspan="1">7 (43.8)</td><td align="center" rowspan="1" colspan="1">15 (48.4)</td><td align="center" rowspan="1" colspan="1">38 (77.5)</td><td align="center" rowspan="1" colspan="1">25 (51.0)</td><td align="center" rowspan="1" colspan="1">209 (64.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital mortality</td><td align="center" rowspan="1" colspan="1">3 (18.8)</td><td align="center" rowspan="1" colspan="1">1 (3.2)</td><td align="center" rowspan="1" colspan="1">3 (6.1)</td><td align="center" rowspan="1" colspan="1">1 (2.0)</td><td align="center" rowspan="1" colspan="1">10 (3.1)</td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><p>CABG=coronary artery bypass graft surgery</p><p>Data presented as number (%) or mean &#x000b1; standard deviation.</p></fn></table-wrap-foot></table-wrap><p>Our study has several limitations. First, our sample of JW was small. However, this
is a non-selected and consecutive cohort of JW and there is no record of denial of
cardiac surgery to any JW at our hospital. Second, surgical data were heterogeneous
between our groups: the rates of combined surgery and valve surgery were higher in
JW than in controls. This can partly explain a trend toward higher mortality rate
among JW in our cohort. Third, this is a cross-sectional retrospective study with
all methodological limitations of such design. Therefore, our results need to be
interpreted in a cautious and exploratory fashion.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, our study demonstrated a high rate of in-hospital mortality in JW and
a trend toward higher mortality in JW than in controls. In addition, we observed
that in our cohort of JW the mortality risk predicted by EuroSCORE II was not
accurate: in fact, EuroSCORE II underestimated surgical risk in JW in our study. To
our knowledge, this is the first Brazilian study to compare outcomes of heart
surgery in JW with controls.</p><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FHV</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FPJ</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BSG</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TMF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VG</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;MG</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Hospital de Cl&#x000ed;nicas de Porto Alegre
(HCPA), Porto Alegre, RS, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GJ</given-names></name><name><surname>Pike</surname><given-names>K</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Wordsworth</surname><given-names>S</given-names></name><name><surname>Stokes</surname><given-names>EA</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Liberal or restrictive transfusion after cardiac
surgery</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>11</issue><fpage>997</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">25760354</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Uriel</surname><given-names>N</given-names></name><name><surname>Asfaw</surname><given-names>Z</given-names></name><name><surname>Onsager</surname><given-names>D</given-names></name><name><surname>Lonchyna</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Cardiovascular surgery in Jehovah's Witness patients: the role of
preoperative optimization</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>150</volume><issue>4</issue><fpage>976</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">26211405</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCartney</surname><given-names>S</given-names></name><name><surname>Guinn</surname><given-names>N</given-names></name><name><surname>Roberson</surname><given-names>R</given-names></name><name><surname>Broomer</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>W</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name></person-group><article-title>Jehovah's Witnesses and cardiac surgery: a single institution's
experience</article-title><source>Transfusion</source><year>2014</year><volume>54</volume><issue>10</issue><issue-part>Pt 2</issue-part><fpage>2745</fpage><lpage>2752</lpage><pub-id pub-id-type="pmid">24809815</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaislic</surname><given-names>CD</given-names></name><name><surname>Dalibon</surname><given-names>N</given-names></name><name><surname>Ponzio</surname><given-names>O</given-names></name><name><surname>Ba</surname><given-names>M</given-names></name><name><surname>Jugan</surname><given-names>E</given-names></name><name><surname>Lagneau</surname><given-names>F</given-names></name><etal/></person-group><article-title>Outcomes in cardiac surgery in 500 consecutive Jehovah's Witness
patients: 21 year experience</article-title><source>J Cardiothorac Surg</source><year>2012</year><volume>7</volume><fpage>95</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">23013647</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>L</given-names></name><name><surname>Krampl</surname><given-names>C</given-names></name><name><surname>Vrtik</surname><given-names>M</given-names></name><name><surname>Haluska</surname><given-names>B</given-names></name><name><surname>Griffin</surname><given-names>R</given-names></name><name><surname>Mundy</surname><given-names>J</given-names></name><etal/></person-group><article-title>term outcomes after cardiac surgery in a Jehovah's Witness
population: an institutional experience</article-title><source>Heart Lung Circ</source><year>2012</year><volume>21</volume><issue>2</issue><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">22047753</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jassar</surname><given-names>AS</given-names></name><name><surname>Ford</surname><given-names>PA</given-names></name><name><surname>Haber</surname><given-names>HL</given-names></name><name><surname>Isidro</surname><given-names>A</given-names></name><name><surname>Swain</surname><given-names>JD</given-names></name><name><surname>Bavaria</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Cardiac surgery in Jehovah's Witness patients: ten-year
experience</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>93</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">21978873</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinakis</surname><given-names>S</given-names></name><name><surname>Van der Linden</surname><given-names>P</given-names></name><name><surname>Tortora</surname><given-names>R</given-names></name><name><surname>Massaut</surname><given-names>J</given-names></name><name><surname>Pierrakos</surname><given-names>C</given-names></name><name><surname>Wauthy</surname><given-names>P</given-names></name></person-group><article-title>Outcomes from cardiac surgery in Jehovah's witness patients:
experience over twenty-one years</article-title><source>J Cardiothorac Surg</source><year>2016</year><volume>11</volume><issue>1</issue><fpage>67</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">27079663</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamou</surname><given-names>SC</given-names></name><name><surname>White</surname><given-names>T</given-names></name><name><surname>Barnett</surname><given-names>S</given-names></name><name><surname>Boyce</surname><given-names>SW</given-names></name><name><surname>Corso</surname><given-names>PJ</given-names></name><name><surname>Lefrak</surname><given-names>EA</given-names></name></person-group><article-title>Comparisons of cardiac surgery outcomes in Jehovah's versus
Non-Jehovah's Witnesses</article-title><source>Am J Cardiol</source><year>2006</year><volume>98</volume><issue>9</issue><fpage>1223</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">17056333</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaskar</surname><given-names>B</given-names></name><name><surname>Jack</surname><given-names>RK</given-names></name><name><surname>Mullany</surname><given-names>D</given-names></name><name><surname>Fraser</surname><given-names>J</given-names></name></person-group><article-title>Comparison of outcome in Jehovah&#x000b4;s Witness patients in cardiac
surgery: an Australian experience</article-title><source>Heart Lung Circ</source><year>2010</year><volume>19</volume><issue>11</issue><fpage>655</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">20813584</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattakos</surname><given-names>G</given-names></name><name><surname>Koch</surname><given-names>CG</given-names></name><name><surname>Brizzio</surname><given-names>ME</given-names></name><name><surname>Batizy</surname><given-names>LH</given-names></name><name><surname>Sabik</surname><given-names>JF 3rd</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Outcome of patients who refuse transfusion after cardiac surgery:
a natural experiment with severe blood conservation</article-title><source>Arch Intern Med</source><year>2012</year><volume>172</volume><issue>15</issue><fpage>1154</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">22751620</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="book"><source>Censo Demogr&#x000e1;fico 2010: Caracter&#x000ed;sticas gerais da
popula&#x000e7;&#x000e3;o, religi&#x000e3;o e pessoas com
defici&#x000ea;ncia</source><comment>[Internet]</comment><publisher-loc>Rio de Janeiro</publisher-loc><publisher-name>Instituto Brasileiro de Geografia e Estat&#x000ed;stica -
IBGE</publisher-name><year>2012</year><date-in-citation content-type="access-date">2016 Nov 6</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ibge.gov.br/">http://www.ibge.gov.br/</ext-link></comment></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Sharples</surname><given-names>LD</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Goldstone</surname><given-names>AR</given-names></name><etal/></person-group><article-title>EuroSCORE II</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>41</volume><issue>4</issue><fpage>734</fpage><lpage>745</lpage><pub-id pub-id-type="pmid">22378855</pub-id></element-citation></ref></ref-list></back></article>